ABOUT US
Enogenesis LLC is a unique applied technology-based specialty pharmaceutical company.
Enogenesis's scientists are focused on delivering Nitric Oxide and our partner’s molecule utilizing
Combination Drug Delivery Platform™ (CDDP) with enhanced therapeutic drug effects for patients.
ENOGENESIS’s development team has written over 30+ papers on nitric oxide and had 30+ years of collective experience in nitric oxide research before developing the nanoparticles over the last four years. ENOGENESIS was formed in 2018 by Robert Kremer and Mahantesh Navati to develop the next generation of nitric oxide (“NO”) more efficient NO production and delivery- with the potential to treat a broad range of respiratory and non-respiratory conditions.
Enogenesis’s Drug Delivery Platform™ of Nitric Oxide is INONOx™.
Our 4000-foot laboratory, located in Bronx, NY is fully equipped and staffed for its present operating requirements and future expansion. Enogenesis's laboratory personnel has many years of working expertise providing NO-specific compounds and their physic-chemical characterizations.
Enogenesis Is focusing on the following therapeutic areas in which Nitric Oxide has scientifically demonstrated its diverse functionality:
-
Anti-bacterial / Anti-viral - MRSA - COVID19 - Oral care
-
Dermal Applications – Beauty Care, OTC Drugs, and Prescription Drugs
-
Anti-fungal: toenail fungus, Candida, and Mucormycosis
-
Pulmonary
Nitric Oxide (“NO”)
Diatomic signaling molecule plays a crucial role in physiological and pathological functions in the human body.
NO has many pathways in regulating cardiovascular functions, drug-resistant, antibacterial, antifungal, antiviral function, the central nervous system, dermatology, oral care, eye care, and ED.
Enogenesis marketing and licensing this important technology and its applications to OTC, pharmaceutical, and personal care companies.
-
INONOx™ is the first complete multifunctional delivery platform for Nitric Oxide applications.
-
INONox is safe, cost-effective, and treats a wide range of health conditions.
-
Nitric Oxide 1998 Molecule of the Year, Nobel Prize In Medicine.
-
Enogenesis’s Combination Drug Delivery Platform™ (CDDP) is a versatile molecule drug delivery technology.
-
With the Efficacy of iNONOx’s CDDP technology, OTC drugs exceed the efficacy of many prescription drugs.
-
INONOx Drug Delivery Platform enables the safe and effective therapeutic administration of Nitric Oxide.
-
INONOx Drug Delivery Platform enables the optimum bioavailability and therapeutic effectiveness of Nitric Oxide.
-
Nitric Oxide is biodegradable, and the Drug Delivery Platform utilizes excipients that are Generally Recognized As Safe (GRAS).
Our Team
Robert Kremer, Co-founder, CEO
Robert Kremer is the co-founder. Founder of nitric oxide laboratory facility and research center. Inventor of Noximed mask insert and NO delivery systems.
Mark Gerard, President
Mr. Gerard has decades of experience in entrepreneurship involving design, construction, and
real estate. He has started multiple businesses in the data center industry and has led large-scale
international projects worth upwards of 1 billion dollars.
Mahantesh S Navati, Ph.D., CTO
Dr. Navati has multi-disciplinary expertise from nanotechnology to bio-electronics that has significantly contributed to various biomedical applications. His wide vision on formulation and development of nano-theranostic systems (combination of diagnostics and therapy) has resulted in over 14 patents (granted/pending) and 30 publications. Dr. Navati received his Ph.D. in Physics in India and specializes in adopting concepts of physics to biomedical application and nanotechnology. Dr. Navati was a senior Scientist in Nanocrystals Technologies, NY, and worked for Bio-SPHERIX, MD, in collaboration with Einstein College of Medicine.
Jyothishree T.J., Laboratory Director
Jimmy K. Lee, M.D
Jimmy is an international leader in the field of laser vision correction, cataract surgery, customized corneal transplants, ocular surface surgery, minimally invasive glaucoma surgery (MIGS), and anterior segment reconstruction. A graduate of Johns Hopkins University, Dr. Lee obtained his medical degree from Cornell University. He completed his ophthalmology residency at Albert Einstein Montefiore Medical Center and Cornea, Cataract, and Refractive Surgery Fellowship at the Johns Hopkins Hospital Wilmer Eye Institute. He has been recognized by Castle Connolly Regional Top Doctors, New York Magazine Top Doctors and Top Doctors New York Metro Area perennially by fellow ophthalmologists. As a member of the Admissions Committee and as an Associate Professor at the Yale School of Medicine and Albert Einstein College of Medicine, Dr. Lee trained and mentored generations of medical students and residents, many of whom are on faculty of prestigious ophthalmological institutions today. In 2021, he was voted as the best surgical teaching professor by ophthalmology residents
Mrs. Jyothishree is the Laboratory Director; she predominantly contributes to the research work and subsidiarily also performs the lab managerial duties. She has vast experience and knowledge in the field of biomedical evaluation of nanoparticles and nano-characterization. She is very well versed in aseptic techniques, assay development, antimicrobial and anti-biofilm studies, and has expertise in various biological skills. Additionally, she has a thorough comprehension of Confocal Imaging. Mrs. Jyothishree has a Bachelor’s Degree in Engineering with distinction, and she aptly implements the engineering concepts to biomedical application.
Shivaleela Keerthy, Research Assistant
Ms. Keerthy has two degrees, M.Sc (Biochemistry) and M.S Biological sciences. She has performed research in trans fatty acids, tumor biology, and AIDS research, Nitric Oxide and drug delivery.
Chetan S. Kolar, Vice President, CDMO Business Development
Chetan is responsible for key account management, marketing, and sales operations as well as sourcing materials and equipment. Chetan brings deep expertise in leading global sales and marketing teams. He has a leadership experience in market development and strategic planning for contract Pharma services value chain from Drug discovery, Development, Manufacturing, and supplies (APIs and FDF). He has worked across various geographies like Europe, Asia pacific and North America wherein he created, built businesses and has been key instrumental in setting up dedicated R&D centers for large pharma organizations. He has master’s in biotechnology and done PG Diploma in business administration